Critical Limb Ischemia clinical trials at UCSF

4 in progress, 2 open to eligible people

Critical limb ischemia is a serious condition where blood flow to the legs is very low. UCSF is testing treatments that use a patient's own blood cells and a method called deep vein arterialization. These studies are looking for new ways to help people with this problem.

Showing trials for

  • BGC101 (EnEPC) Autologous Cell Therapy From Patient's Own Blood for Treatment of Critical Limb Ischemia (CLI)

    open to eligible people ages 18 years and up

    Evaluate the feasibility of an autologous cell preparation composed of a mixture of cells enriched for endothelial progenitor cells (EnEPCs) and multipotent adult hematopoietic stem/progenitor cells (HSPC) (BGC101), in the treatment of patients suffering from peripheral arterial disease (PAD) with critical limb ischemia (CLI) who have not responded to optimal pharmacological treatment or control of risk factors and/or had a revascularization failure, and do not have the option of further revascularization treatment.

    San Francisco, California and other locations

  • PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

    open to eligible people ages 18-95

    A prospective, single-arm, multi-center study designed to gather additional information on the LimFlow System.

    San Francisco, California and other locations

  • LIFE-BTK Randomized Controlled Trial

    Sorry, in progress, not accepting new patients

    The objective of this prospective, single-blinded, randomized controlled clinical investigation is to evaluate the safety and efficacy of the everolimus eluting Esprit BTK System for the planned treatment of narrowed infrapopliteal lesions. Approximately 225 subjects will be randomized in a 2:1 ratio. The clinical investigation will be conducted at approximately 65 clinical sites in the US, Asia, Australia, and New Zealand.

    Fresno, California and other locations

  • PROMISE II: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

    Sorry, in progress, not accepting new patients

    The LimFlow System is intended for endovascular, minimally invasive procedures in patients who have a clinical diagnosis of chronic limb-threatening ischemia and who have been determined to have no surgical or endovascular treatment option (i.e., "no option").

    San Francisco, California and other locations

Last updated: